To include your compound in the COVID-19 Resource Center, submit it here.

Spring Bank’s HBV therapy on hold after signs of liver damage

Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies with the same mechanism will

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE